Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Applied DNA Sciences Inc APDN

Technology Scientific & Technical Instruments
Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic... see more

Recent & Breaking News (NDAQ:APDN)

Applied DNA Announces 1-For-20 Reverse Stock Split

Accesswire 2 days ago

Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start

Accesswire March 18, 2024

Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress

Accesswire March 14, 2024

Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results

Accesswire February 8, 2024

Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024

Accesswire February 5, 2024

Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Accesswire February 2, 2024

Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Accesswire January 31, 2024

Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology's mRNA Manufacturing Workflow

Accesswire December 14, 2023

Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results

Accesswire December 7, 2023

Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023

Accesswire December 5, 2023

Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application

Accesswire November 28, 2023

Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)

Accesswire November 16, 2023

Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform

Accesswire November 9, 2023

Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals

Accesswire September 14, 2023

Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs

Accesswire September 6, 2023

Applied DNA Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit

Accesswire August 29, 2023

Applied DNA Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production

Accesswire August 23, 2023

Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update

Accesswire August 10, 2023

Applied DNA to Report Third Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, August 10, 2023

Accesswire August 7, 2023

Applied DNA Biotherapeutics Subsidiary LineaRx to Participate in Upcoming mRNA Industry Conferences

Accesswire July 18, 2023